CONMED Corporation (CNMD)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	64,459	57,972	88,285	-93,738	-80,582	-82,722	-113,924	67,657	62,542	62,238	54,140	13,450	9,517	310	430	33,525	28,619	29,339	28,194	31,218
Total stockholders’ equity	US$ in thousands	834,222	796,205	780,194	752,453	745,545	716,337	672,968	789,546	785,435	755,683	744,499	725,570	709,038	683,141	674,898	701,635	710,467	700,922	697,009	693,057
ROE		7.73%	7.28%	11.32%	-12.46%	-10.81%	-11.55%	-16.93%	8.57%	7.96%	8.24%	7.27%	1.85%	1.34%	0.05%	0.06%	4.78%	4.03%	4.19%	4.04%	4.50%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $64,459K ÷ $834,222K
= 7.73%

To analyze Conmed Corp.'s return on equity (ROE) based on the provided data, we can observe the trend over the quarters:

1. Q4 2023: ROE is 7.73%, showing a slight increase compared to the previous quarter.
2. Q3 2023: ROE is 7.28%, maintaining stability compared to the preceding quarter.
3. Q2 2023: ROE is 11.32%, indicating a significant increase in profitability.
4. Q1 2023: ROE is -12.46%, a notable decrease from the previous quarter, reflecting a negative return on equity.
5. Q4 2022: ROE is -10.81%, showing a slight improvement compared to the third quarter of 2022.
6. Q3 2022: ROE is -11.55%, indicating a slightly lower ROE compared to the second quarter of 2022.
7. Q2 2022: ROE is -16.93%, showing a significant decline in profitability.
8. Q1 2022: ROE is 8.57%, indicating a positive return on equity in the first quarter of 2022.

Overall, Conmed Corp.'s ROE has demonstrated fluctuations in profitability over the quarters, with a mix of positive and negative returns. The company experienced a notable increase in profitability in Q2 2023, following periods of negative ROE in earlier quarters. It is essential for stakeholders to further investigate the factors contributing to these fluctuations in ROE to gain a deeper understanding of the company's financial performance and future prospects.